Quality of Life in Treatment-Resistant Hypertension

Current Hypertension Reports

Volumn 17, Issue 8, 2015, Pages

  Carris, Nicholas W ^a   Smith, Steven M ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Hypertension; Patient reported outcome; Quality of life; Resistant hypertension

Indexed keywords

ANTIHYPERTENSIVE THERAPY; ANXIETY; AWARENESS; BLOOD PRESSURE FLUCTUATION; BLOOD PRESSURE REGULATION; FUNCTIONAL STATUS; HUMAN; MENTAL FUNCTION; OUTCOME ASSESSMENT; QUALITY OF LIFE; RESISTANT HYPERTENSION; REVIEW; STRESS; BLOOD PRESSURE MEASUREMENT; HYPERTENSION; TREATMENT OUTCOME;

ANXIETY; BLOOD PRESSURE DETERMINATION; HUMANS; HYPERTENSION; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84933049934     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-015-0578-5     Document Type: Review

References (80)

1. Fisher JW. The diagnostic value of the sphygmomanometer in examinations for life insurance. JAMA. 1914;LXIII:1752–4.
2. Rahimi K, Emdin CA, MacMahon S. The epidemiology of blood pressure and its worldwide management. Circ Res. 2015;116(6):925–36.
3. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303(20):2043–50.
4. Wang H, Dwyer-Lindgren L, Lofgren KT, et al. Age-specific and sex-specific mortality in 187 countries, 1970–2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2071–94.
5. Falaschetti E, Mindell J, Knott C, Poulter N. Hypertension management in England: a serial cross-sectional study from 1994 to 2011. Lancet. 2014;383(9932):1912–9.
6. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Eur Heart J. 2013;31(7):1281–357.
7. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.
8. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington DC: National Academy Press; 2001.
9. Rumsfeld JS, Alexander KP, Goff Jr DC, et al. Cardiovascular health: the importance of measuring patient-reported health status: a scientific statement from the American heart association. Circulation. 2013;127(22):2233–49.
10. Vemulapalli S, Ard J, Bakris GL, et al. Proceedings from duke resistant hypertension think tank. Am Heart J. 2014;167(6):775–788.e771.
11. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217–23.
12. Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension–its identification and epidemiology. Nat Rev Nephrol. 2013;9(1):51–8.
13. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American heart association professional education committee of the council for high blood pressure research. Hypertension. 2008;51(6):1403–19.
14. Smith SM, Gong Y, Handberg E, et al. Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens. 2014;32(3):635–43.
15. Smith SM, Huo T, Delia Johnson B, et al. Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE study. J Am Heart Assoc. 2014;3(1), e000660.
16. Kumbhani DJ, Steg PG, Cannon CP, et al. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013;34(16):1204–14.
17. De Nicola L, Gabbai FB, Agarwal R, et al. Prevalence and prognostic role of resistant hypertension in chronic kidney disease patients. J Am Coll Cardiol. 2013;61(24):2461–7.
18. Irvin MR, Booth 3rd JN, Shimbo D, et al. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens. 2014;8(6):405–13.
19. Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Hypertension. 2014;64(5):1012–21.
20. Stewart AL, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions. Results from the medical outcomes study. JAMA. 1989;262(7):907–13.
21. Bardage C, Isacson DG. Hypertension and health-related quality of life. An epidemiological study in Sweden. J Clin Epidemiol. 2001;54(2):172–81.
22. Mena-Martin FJ, Martin-Escudero JC, Simal-Blanco F, Carretero-Ares JL, Arzua-Mouronte D, Herreros-Fernandez V. Health-related quality of life of subjects with known and unknown hypertension: results from the population-based hortega study. J Hypertens. 2003;21(7):1283–9.
23. Alonso J, Ferrer M, Gandek B, et al. Health-related quality of life associated with chronic conditions in eight countries: results from the international quality of life assessment (IQOLA) project. Qual Life Res. 2004;13(2):283–98.
24. Arslantas D, Ayranci U, Unsal A, Tozun M. Prevalence of hypertension among individuals aged 50 years and over and its impact on health related quality of life in a semi-rural area of western Turkey. Chin Med J (Engl). 2008;121(16):1524–31.
25. Wang R, Zhao Y, He X, et al. Impact of hypertension on health-related quality of life in a population-based study in Shanghai, China. Public Health. 2009;123(8):534–9.
26. Erickson SR, Williams BC, Gruppen LD. Perceived symptoms and health-related quality of life reported by uncomplicated hypertensive patients compared to normal controls. J Hum Hypertens. 2001;15(8):539–48.
27. Moum T, Naess S, Sorensen T, Tambs K, Holmen J. Hypertension labelling, life events and psychological well-being. Psychol Med. 1990;20(3):635–46.
28. DeForge BR, Stewart DL, DeVoe-Weston M, Graham L, Charleston J. The relationship between health status and blood pressure in urban African Americans. J Natl Med Assoc. 1998;90(11):658–64.
29. Trevisol DJ, Moreira LB, Kerkhoff A, Fuchs SC, Fuchs FD. Health-related quality of life and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2011;29(2):179–88.
30. Trevisol DJ, Moreira LB, Fuchs FD, Fuchs SC. Health-related quality of life is worse in individuals with hypertension under drug treatment: results of population-based study. J Hum Hypertens. 2012;26(6):374–80. This study showed that health-related quality of life is lowest in individuals with treated, controlled blood pressure, followed by those with treated, uncontrolled blood pressure, whereas those with untreated, uncontrolled blood pressure reported the greatest quality of life scores.
31. Korhonen PE, Kivela SL, Kautiainen H, Jarvenpaa S, Kantola I. Health-related quality of life and awareness of hypertension. J Hypertens. 2011;29(11):2070–4.
32. Li W, Liu L, Puente JG, et al. Hypertension and health-related quality of life: an epidemiological study in patients attending hospital clinics in China. J Hypertens. 2005;23(9):1667–76.
33. Spruill TM, Gerber LM, Schwartz JE, Pickering TG, Ogedegbe G. Race differences in the physical and psychological impact of hypertension labeling. Am J Hypertens. 2012;25(4):458–63.
34. Hayes DK, Denny CH, Keenan NL, Croft JB, Greenlund KJ. Health-related quality of life and hypertension status, awareness, treatment, and control: National Health and Nutrition Examination Survey, 2001–2004. J Hypertens. 2008;26(4):641–7.
35. Maatouk I, Wild B, Herzog W, et al. Longitudinal predictors of health-related quality of life in middle-aged and older adults with hypertension: results of a population-based study. J Hypertens. 2012;30(7):1364–72.
36. Spruill TM, Feltheimer SD, Harlapur M, et al. Are there consequences of labeling patients with prehypertension? an experimental study of effects on blood pressure and quality of life. J Psychosom Res. 2013;74(5):433–8.
37. O’Brien E. If I had resistant hypertension. Hypertension. 2014;64(5):e3–6.
38. Gong Y, Handberg EM, Gerhard T, et al. Systolic blood pressure and subjective well-being in patients with coronary artery disease. Clin Cardiol. 2009;32(11):627–32.
39. Zygmuntowicz M, Owczarek A, Elibol A, Olszanecka-Glinianowicz M, Chudek J. Blood pressure for optimal health-related quality of life in hypertensive patients. J Hypertens. 2013;31(4):830–9. This study showed the blood pressure level associated with optimal health-related quality of life in persons with treatment-resistant hypertension and that this blood pressure level is considerably greater in those with treatment-resistant hypertension than in those with non-resistant hypertension.
40. Carris NW, Ghushchyan V, Libby AM, Smith SM. Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives. J Hum Hypertens 2015. doi:10.1038/jhh.2015.61. This study showed that health-related quality of life with regard to physical functioning is demonstrably worse in those with treatment-resistant hypertension compared to those with non-resistant hypertension, as well as the inverse association between number of medications and health-related quality of life.
41. Applegate WB. Quality of life during antihypertensive treatment. Lessons from the systolic hypertension in the elderly program. Am J Hypertens. 1998;11(3 Pt 2):57s–61s.
42. Fletcher AE, Bulpitt CJ, Thijs L, et al. Quality of life on randomized treatment for isolated systolic hypertension: results from the syst-Eur trial. J Hypertens. 2002;20(10):2069–79.
43. Peters R, Beckett N, McCormack T, Fagard R, Fletcher A, Bulpitt C. Treating hypertension in the very elderly-benefits, risks, and future directions, a focus on the hypertension in the very elderly trial. Eur Heart J. 2014;35(26):1712–8.
44. Croog SH, Levine S, Testa MA, et al. The effects of antihypertensive therapy on the quality of life. N Engl J Med. 1986;314(26):1657–64.
45. Testa MA, Anderson RB, Nackley JF, Hollenberg NK. Quality of life and antihypertensive therapy in men. A comparison of captopril with enalapril. The quality-of-life hypertension study group. N Engl J Med. 1993;328(13):907–13.
46. Fogari R, Zoppi A. Effect of antihypertensive agents on quality of life in the elderly. Drugs Aging. 2004;21(6):377–93.
47. Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens. 2005;18(8):1060–6.
48. Kusek JW, Lee JY, Smith DE, et al. Effect of blood pressure control and antihypertensive drug regimen on quality of life: the African American study of kidney disease and hypertension (AASK) pilot study. Control Clin Trials. 1996;17(4 Suppl):40s–6s.
49. Egan BM, Zhao Y, Li J, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension. 2013;62(4):691–7.
50. Hanselin MR, Saseen JJ, Allen RR, Marrs JC, Nair KV. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension. 2011;58(6):1008–13.
51. Williams GH, Croog SH, Levine S, Testa MA, Sudilovsky A. Impact of antihypertensive therapy on quality of life: effect of hydrochlorothiazide. J Hypertens Suppl. 1987;5(1):S29–35.
52. Ripley TL, Saseen JJ. Beta-blockers: a review of their pharmacological and physiological diversity in hypertension. Ann Pharmacother. 2014;48(6):723–33.
53. Mancia G, Zambon A, Soranna D, Merlino L, Corrao G. Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data. J Hypertens. 2014;32(8):1708–15.
54. Degli Esposti E, Sturani A, Di Martino M, et al. Long-term persistence with antihypertensive drugs in new patients. J Hum Hypertens. 2002;16(6):439–44.
55. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens. 2002;16(8):569–75.
56. Caro JJ, Speckman JL, Salas M, Raggio G, Jackson JD. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160(1):41–6.
57. Bourgault C, Senecal M, Brisson M, Marentette MA, Gregoire JP. Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study. J Hum Hypertens. 2005;19(8):607–13.
58. Elliott WJ, Plauschinat CA, Skrepnek GH, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. J Am Board Fam Med. 2007;20(1):72–80.
59. Lambert GW, Hering D, Esler MD, et al. Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension. 2012;60(6):1479–84. This small study found that health-related quality of life was lower in persons with significantly uncontrolled treatment-resistant hypertension than those with controlled non-resistant hypertension and that renal denervation therapy was associated with only modest, if any, improvement in quality of life.
60. Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care. 2003;41(5):582–92.
61. Lenski D, Kindermann I, Lenski M, et al. Anxiety, depression, quality of life and stress in patients with resistant hypertension before and after catheter-based renal sympathetic denervation. EuroIntervention. 2013;9(6):700–8.
62. Brandt MC, Reda S, Mahfoud F, Lenski M, Bohm M, Hoppe UC. Effects of renal sympathetic denervation on arterial stiffness and central hemodynamics in patients with resistant hypertension. J Am Coll Cardiol. 2012;60(19):1956–65.
63. Xie J, Wu EQ, Zheng ZJ, Sullivan PW, Zhan L, Labarthe DR. Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences. Circulation. 2008;118(5):491–7.
64. Xie J, Wu EQ, Zheng ZJ, et al. Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States. Stroke. 2006;37(10):2567–72.
65. Fu AZ, Qiu Y, Radican L, Luo N. Marginal differences in health-related quality of life of diabetic patients with and without macrovascular comorbid conditions in the United States. Qual Life Res. 2011;20(6):825–32.
66. Sullivan PW, Smith KL, Ghushchyan VH, Globe DR, Lin SL, Globe G. Asthma in USA: its impact on health-related quality of life. J Asthma. 2013;50(8):891–9.
67. Sullivan PW, Ghushchyan VH, Ben-Joseph R. The impact of obesity on diabetes, hyperlipidemia and hypertension in the United States. Qual Life Res. 2008;17(8):1063–71.
68. Zivin K, McCarthy JF, McCammon RJ, et al. Health-related quality of life and utilities among patients with depression in the department of Veterans affairs. Psychiatr Serv. 2008;59(11):1331–4.
69. Schmieder RE, Grassi G, Kjeldsen SE. Patients with treatment-resistant hypertension report increased stress and anxiety: a worldwide study. J Hypertens. 2013;31(3):610–5. This survey study demonstrated that treatment-resistant hypertension is associated with substantially greater stress and anxiety than non-resistant hypertension.
70. Smith SM. Epidemiology, prognosis, and treatment of resistant hypertension. Pharmacotherapy. 2013;33(10):1071–86.
71. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry. 2000;157(5):669–82.
72. Brinker S, Pandey A, Ayers C, et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63(8):834–5.
73. Florczak E, Tokarczyk B, Warchol-Celinska E, et al. Assessment of adherence to treatment in patients with resistant hypertension using toxicological serum analysis: a subgroup evaluation of the RESIST-POL study. Pol Arch Med Wewn. 2015;125(1–2):65–72.
74. Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31:766–74.
75. Hameed MA, Tebbit L, Jacques N, et al. Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic. J Hum Hypertens. 2015. doi:10.1038/jhh.2015.38.
76. Holt EW, Muntner P, Joyce CJ, et al. Health-related quality of life and antihypertensive medication adherence among older adults. Age Aging. 2010;39:481–7.
77. Zyoud SH, Al-Jabi SW, Sweileh WM, et al. Health-related quality of life associated with treatment adherence in patients with hypertension: a cross-sectional study. Int J Cardiol. 2013;168:2981–3.
78. Trivedi RB, Ayotte B, Edelman D, Bosworth HB. The association of emotional well-being and marital status with treatment adherence among patients with hypertension. J Behav Med. 2008;31:489–97.
79. Pippalla RS, Chinburapa V, Duval R, Akula RS. Interrelationships of quality of life, compliance, clinical outcomes and life satisfaction: a cross-sectional study on hypertensive geriatrics. J Clin Pharm Ther. 1997;22:357–69.
80. Cote I, Farris K, Feeny D. Is adherence to drug treatment correlated with health-related quality of life? Qual Life Res. 2003;12:621–33.